Fulcrum Therapeutics’ (FULC) Sector Perform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reissued their sector perform rating on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a research report report published on Thursday,Benzinga reports. They currently have a $4.00 price target on the stock.

Several other research analysts have also recently weighed in on the company. Bank of America cut Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and reduced their price target for the company from $10.00 to $2.00 in a research report on Thursday, September 12th. Leerink Partnrs lowered shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Leerink Partners reissued a “market perform” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a report on Thursday, September 12th. Stifel Nicolaus cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and cut their price objective for the company from $22.00 to $3.00 in a report on Thursday, September 12th. Finally, Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Thursday, September 12th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $9.33.

Fulcrum Therapeutics Stock Performance

Shares of FULC opened at $3.01 on Thursday. The business’s 50-day moving average is $3.75 and its two-hundred day moving average is $6.48. The company has a market capitalization of $187.51 million, a P/E ratio of -9.69 and a beta of 2.24. Fulcrum Therapeutics has a fifty-two week low of $2.87 and a fifty-two week high of $13.70.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Fulcrum Therapeutics during the 1st quarter worth approximately $308,000. SG Americas Securities LLC purchased a new stake in shares of Fulcrum Therapeutics during the first quarter worth approximately $115,000. Vanguard Group Inc. raised its stake in Fulcrum Therapeutics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 2,538,665 shares of the company’s stock valued at $23,965,000 after purchasing an additional 18,681 shares during the last quarter. StemPoint Capital LP lifted its holdings in Fulcrum Therapeutics by 8.1% in the 1st quarter. StemPoint Capital LP now owns 407,108 shares of the company’s stock valued at $3,843,000 after purchasing an additional 30,535 shares in the last quarter. Finally, Jane Street Group LLC boosted its stake in Fulcrum Therapeutics by 54.3% during the 1st quarter. Jane Street Group LLC now owns 535,062 shares of the company’s stock worth $5,051,000 after purchasing an additional 188,212 shares during the last quarter. 89.83% of the stock is owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.